CI

At a glance

ClinicalIndex Comparison Record
N/ANot Yet Recruiting· 32 target
Drug / intervention
Washed Microbiota Transplantation +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06372184
NCT06372184N/ANot Yet Recruiting

Efficacy and Safety of Washed Microbiota Transplantation for Allergic Rhinitis: A Randomized, Double-blind, Placebo-controlled Study

The Second Hospital of Nanjing Medical University·interventional·Posted Apr 17, 2024·Updated May 7, 2024

In Brief

A clinical study evaluating Washed Microbiota Transplantation and Placebo for Rhinitis, Allergic. Not yet recruiting, targeting 32 participants across 1 site.

Detailed Summary

Allergic rhinitis (AR) is characterized by sneezing, nasal congestion, nasal itching and nasal leakage and is caused by immunoglobulin E (IgE)-mediated reactions to inhaled allergens. Increasing evidence showed that gut microbiota could influence the development of AR, and we found that washed microbiota transplantation (WMT) could improve nasal symptoms in clinical practice. This clinical trial aims to evaluate the efficacy and safety of WMT for AR.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--

Timeline

N/ANot Yet Recruiting
20252026202720282029
First PostedApr 17, 2024
Enrollment StartJun 1, 2024
Primary CompletionJun 1, 2029
Study CompletionOct 1, 2029
TodayJul 1, 2026
Enrollment to primary: 5 yearsPosted 2.2 years agoPrimary completion in 2.9 years

Interventions

Washed Microbiota Transplantationdrug

Patients take four capsules containing washed microbiota once a day for five consecutive days

Placebodrug

Patients take four capsules in the same packaging as the experimental group once a day for five consecutive days